Premium
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2‐year study evaluation
Author(s) -
Derosa Giuseppe,
Ragonesi Pietro Dario,
Fogari Elena,
Cicero Arrigo Francesco Giuseppe,
Bianchi Lucio,
Bonaventura Aldo,
Romano Davide,
Maffioli Pamela
Publication year - 2014
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12001
Subject(s) - sitagliptin , medicine , sitagliptin phosphate , insulin resistance , endocrinology , postprandial , glycemic , lipid profile , glycated hemoglobin , insulin , cholesterol , placebo , type 2 diabetes , diabetes mellitus , alternative medicine , pathology
Abstract The aim of this study was to evaluate whether the positive effects of sitagliptin on glycemic control and insulin resistance were maintained also after 2 years of therapy and whether sitagliptin could be effective also in improving lipid profile. In this randomized, double‐blind, placebo‐controlled trial, 205 patients with type 2 diabetes in therapy with different antidiabetic drugs were randomized to add sitagliptin 100 mg once a day or placebo to their current therapy. We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin ( H b A 1c ), fasting plasma glucose ( FPG ), postprandial plasma glucose ( PPG ), fasting plasma insulin ( FPI ), homeostasis model assessment insulin resistance index ( HOMA ‐ IR ), total cholesterol ( TC ), high‐density lipoprotein cholesterol ( HDL ‐C), low‐density lipoprotein cholesterol ( LDL ‐C), triglycerides ( T g). Sitagliptin, added to previously taken antidiabetic agents, proved to be effective in improving glycemic profile, reducing H b A 1c by −17.5%, FPG by −12.7%, PPG by −20.5%. Regarding insulin resistance, sitagliptin decreased FPI by −8.3% and HOMA ‐ IR by −20.0%, confirming that what have been already reported in short‐term studies can be applied also after 2 years of treatment. Sitagliptin also reduced body weight by −4.3%. Our study also showed the positive effect of sitagliptin on lipid profile; in particular, sitagliptin decreased TC by −13.3%, LDL ‐C by −20.4%, and T g by −32.3%, and also increased HDL ‐ C by + 13.6%. Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile.